Document Detail


Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
MedLine Citation:
PMID:  23007746     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Studies have shown that achieving adequate exposure of mycophenolic acid (MPA) early post transplant is associated with less acute rejection in kidney recipients. Intensified dosing with the equivalent of mycophenolate mofetil (MMF) 3 g daily in tacrolimus-treated patients has been shown to increase exposure however about 15% remain below the lower therapeutic threshold of MPA area under the curve (AUC) of 30 mg · hr⁻¹ · L⁻¹ early post transplant. A post hoc analysis of this study showed that a target MPA AUC >40 mg · hr⁻¹ · L⁻¹ was most effective. The primary objective of this study was to determine whether 4 g daily of MMF would result in a greater proportion achieving adequate MPA exposure.
MATERIALS AND METHODS: MMF 4 g daily was used in tacrolimus treated de novo kidney transplant recipients. A 3-point limited sample strategy was used to measure MPA AUC on days 5 and 14. Doses were adjusted at day 5 if exposure was high.
RESULTS: In 30 patients, the mean AUC was 63 ± 28 mg · hr⁻¹ · L⁻¹ on day 5, with 13% (4/30) ≤ 30 mg · hr⁻¹ · L⁻¹ and 57% (17/30) >60 mg · hr⁻¹ · L⁻¹. The target MPA AUC was <40 mg · hr⁻¹ · L⁻¹ in 23% (7/30). Three patients developed gastrointestinal toxicity and required dose changes. Acute rejection occurred in only 2 patients (grade 1A and 2B) within 3 months (day 5 MPA AUCs were 29.9 and 33 mg · hr⁻¹ · L⁻¹. On day 14 the mean AUC was 46 ± 17 mg · hr⁻¹ · L⁻¹. Many were on MMF doses >2 g daily (8 on 3 g and 9 on 4 g daily).
CONCLUSION: Compared to MMF 3 g daily, 4 g daily dose not result in a greater proportion adequately exposed. Rejections were few and occurred in the lower MPA exposed recipients. More than 50% of patients needed doses of MMF >2 g daily for 2 weeks to avoid underexposure. If intensified MPA dosing is considered, exceeding 3 g daily in tacrolimus-treated patients provides no added benefit.
Authors:
Bryce A Kiberd; Joseph Lawen; Christopher Daley
Related Documents :
17209666 - Fixed-dose combination lercanidipine/enalapril.
11011336 - Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide vers...
396086 - Effect of increasing doses of labetalol on blood pressure, plasma renin activity and al...
18388356 - Acetazolamide for monge's disease: efficiency and tolerance of 6-month treatment.
1651856 - Neuromuscular effects of pipecuronium bromide.
16377676 - In vivo efficacies and pharmacokinetics of dx-619, a novel des-fluoro(6) quinolone, aga...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Therapeutic drug monitoring     Volume:  34     ISSN:  1536-3694     ISO Abbreviation:  Ther Drug Monit     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-15     Completed Date:  2013-04-29     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  7909660     Medline TA:  Ther Drug Monit     Country:  United States    
Other Details:
Languages:  eng     Pagination:  736-8     Citation Subset:  IM    
Affiliation:
Department of Medicine, Dalhousie University, Halifax, Canada. bryce.kiberd@dal.ca
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00943228
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Dose-Response Relationship, Drug
Drug Interactions
Drug Monitoring
Drug Therapy, Combination / adverse effects
Female
Graft Rejection / prevention & control*
Humans
Immunosuppressive Agents / administration & dosage*,  adverse effects,  therapeutic use
Kidney Transplantation / adverse effects*
Male
Middle Aged
Mycophenolic Acid / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Pilot Projects
Prodrugs / administration & dosage*,  adverse effects,  therapeutic use
Tacrolimus / adverse effects,  therapeutic use
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 0/Prodrugs; 109581-93-3/Tacrolimus; 24280-93-1/Mycophenolic Acid; 9242ECW6R0/mycophenolate mofetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Implementation of a Cost-Effective HPLC/UV Approach for Routine Medical Quantification of Memantine ...
Next Document:  Pharmacokinetics of tacrolimus during pregnancy.